Hyperthyroidism and cation pumps in human skeletal muscle.
Skeletal muscle constitutes the major target organ for the thermogenic action of thyroid hormone. We examined the possible relation between energy expenditure (EE), thyroid status, and the contents of Ca2+-ATPase and Na+-K+-ATPasein human skeletal muscle. Eleven hyperthyroid patients with Graves' disease were studied before and after medical treatment with methimazole and compared with eight healthy subjects. Muscle biopsies were taken from the vastus lateralis muscle, and EE was determined by indirect calorimetry. Before treatment, the patients had two- to fivefold elevated total plasma T3 and 41% elevated EE compared with when euthyroidism had been achieved. In hyperthyroidism, the content of Ca2+-ATPase was increased: (mean +/- SD) 6,555 +/- 604 vs. 5,212 +/- 1,580 pmol/g in euthyroidism (P = 0.04) and 4,523 +/- 1,311 pmol/g in healthy controls (P = 0.0005). The content of Na+-K+-ATPase showed 89% increase in hyperthyroidism: 558 +/- 101 vs. 296 +/- 34 pmol/g (P = 0.0001) in euthyroidism and 278 +/- 52 pmol/g in healthy controls (P < 0.0001). In euthyroidism, the contents of both cation pumps did not differ from those of healthy controls. The Ca2+-ATPase content was significantly correlated to plasma T3 and resting EE. This provides the first evidence that, in human skeletal muscle, the capacity for Ca2+ recycling and active Na+-K+ transport are correlated to EE and thyroid status.
Riis
Anne Lene Dalkjaer
AL
Medical Dept. M (Endocrinology and Diabetes), Aarhus Univ. Hospital, 8000 Aarhus C, Denmark. anne.lene.riis@ki.au.dk
Jørgensen
Jens Otto Lunde
JO
Møller
Niels
N
Weeke
Jørgen
J
Clausen
Torben
T
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D001706:Biopsy; D000252:Calcium-Transporting ATPases / Q000378:metabolism*; D002153:Calorimetry, Indirect; D004734:Energy Metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000201:enzymology*; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*
D013956:Antithyroid Agents; D008713:Methimazole; D000252:Calcium-Transporting ATPases; D000254:Sodium-Potassium-Exchanging ATPase